Anti-Wolbachia drug discovery and development: safe macrofilaricides for onchocerciasis and lymphatic filariasis - PubMed (original) (raw)

Review

Anti-Wolbachia drug discovery and development: safe macrofilaricides for onchocerciasis and lymphatic filariasis

Mark J Taylor et al. Parasitology. 2014 Jan.

Abstract

Anti-Wolbachia therapy delivers safe macrofilaricidal activity with superior therapeutic outcomes compared to all standard anti-filarial treatments, with the added benefit of substantial improvements in clinical pathology. These outcomes can be achieved, in principle, with existing registered drugs, e.g. doxycycline, that are affordable, available to endemic communities and have well known, albeit population-limiting, safety profiles. The key barriers to using doxycycline as an mass drug administration (MDA) strategy for widespread community-based control are the logistics of a relatively lengthy course of treatment (4-6 weeks) and contraindications in children under eight years and pregnancy. Therefore, the primary goal of the anti-Wolbachia (A·WOL) consortium is to find drugs and regimens that reduce the period of treatment from weeks to days (7 days or less), and to find drugs which would be safe in excluded target populations (pregnancy and children). A secondary goal is to refine regimens of existing antibiotics suitable for a more restricted use, prior to the availability of a regimen that is compatible with MDA usage. For example, for use in the event of the emergence of drug-resistance, in individuals with high loiasis co-infection and at risk of severe adverse events (SAE) to ivermectin, or in post-MDA 'endgame scenarios', where test and treat strategies become more cost effective and deliverable.

PubMed Disclaimer

Figures

Fig. 1.

Fig. 1.

Screening funnel developed for A·WOL.

Similar articles

Cited by

References

    1. Amazigo U. (2008). The African Programme for Onchocerciasis Control (APOC). Annals of Tropical Medicine and Parasitology 102(Suppl 1), 19–22.10.1179/136485908X337436 - DOI - PubMed
    1. Ash L. R. and Riley J. M. (1970). Development of subperiodic Brugia malayi in the jird, Meriones unguiculatus, with notes on infections in other rodents. Journal of Parasitology 56, 969–973 - PubMed
    1. Bockarie M. J. and Deb R. (2010). Elimination of lymphatic filariasis: do we have the drugs to complete the job? Current Opinion in Infectious Diseases 23, 617–620.10.1097/QCO.0b013e32833fdee5 - DOI - PubMed
    1. Chu B. K., Hooper P. J., Bradley M. H., McFarland D. A. and Ottesen E. A. (2010). The economic benefits resulting from the first 8 years of the Global Programme to Eliminate Lymphatic Filariasis (2000–2007). PLoS Neglected Tropical Diseases 4, e708.10.1371/journal.pntd.0000708 - DOI - PMC - PubMed
    1. Coffeng L. E., Stolk W. A., Zouré H. G., Veerman J. L., Agblewonu K. B., Murdoch M. E., Noma M., Fobi G., Richardus J. H., Bundy D. A., Habbema D., de Vlas S. J. and Amazigo U. V. (2013). African Programme For Onchocerciasis Control 1995–2015: model-estimated health impact and cost. PLoS Neglected Tropical Diseases 7, e2032.10.1371/journal.pntd.0002032 - DOI - PMC - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources